1.7856.25% ( +0.105 )
Trading: Nov 20, 14:28:44 (EDT)Overview
Pyxis Oncology (PYXS)
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) produc...
- Open
- 1.700
- High
- 1.990
- Low
- 1.700
- Prev. Close
- 1.680
- Volume
- 2.52M
- Turnover
- 4.70M
- Avg Price
- 1.866
- Bid/Ask Ratio
- -54.87%
- Amplitude
- 17.26%
- 52wk High
- 5.550
- Volume Ratio
- 2.38
- Turnover Ratio
- 4.28%
- 52wk Low
- 1.030
- Float Mkt Cap
- 105.09M
- Market CapUSD
- 213.50M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.725
- EPSDynamic
- -0.668
- EPSStatic
- --
- BVPS
- 0.35
- P/B
- 5.17
- Circulating Supply
- 58.87M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 119.61M
- Min lot size
- 1
- Currency
- USD
Pyxis Oncology Analyst Rating
View moreForecast & Rating
Nov 20, 2026Price forecast
$8.22360.63%
Forecast & RatingStrong buy
9analysts
- Strong buy77.78%
- Buy11.11%
- Hold11.11%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 7
- Buy
- 1
- Hold
- 1
- Sell
- 0
- Strong sell
- 0
News
benzinga_article · This Tesla Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday
Tip Ranks · Guggenheim Remains a Buy on Pyxis Oncology (PYXS)
TradingView · William Blair upgrades Pyxis Oncology to Outperform from Market Perform
Market Movers · Pyxis Oncology surges 16% on 39% response rate in MICVO Phase I update
Quartr · PYXS: MICVO showed durable responses in phase 1, supporting a planned global Phase 3 trial
